Chempolis to supply three biorefineries to China
Chempolis has signed a licence and EPC agreement with Tianjin Jiuqian Paper Co Ltd. to supply three formico® biorefineries, each capable of producing 100,000 t/a of bleached wheat straw pulp. The new plants are scheduled to start up in 2012-2013.
Chempolis’ scope of supply will cover formico® technology licence and supplying EPC services (engineering, procurement, commissioning and start-up services). The biorefineries will incorporate Chempolis’ latest formicofib™ technologies. The value of the order exceeds EUR 60 million.
“Many paper companies are now focusing on solutions that would help save forest resources, and Chempolis’ formicofib™ technology offers an excellent way of refining residual local non-wood biomass into high-quality papermaking fibres and biochemicals,” which can be distributed locally too”, says Esa Rousu, the President and CEO of Chempolis Ltd.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Genes against drought

Fierce competition between the human immune system and bacterial pathogens - New insights into the recent development of the human immune system

Merck off to a Good Start in Fiscal 2024 - The positive development of Healthcare and Electronics largely compensated for the decline in Life Science
'Tearless' onions could help in the fight against cardiovascular disease
Charles_McIlvaine
Agendia expands its business activities in Germany
Drägerwerk: Turnaround program already saved around EUR 45 million in 2009
Bacteria on marine sponges can develop capacity to move and inhibit biofilm formation

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology - Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement
